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Abstract Travel health providers are often confronted with
complex scenarios when advising travelers on malaria pre-
vention. Current challenges in prevention include malaria risk
assessment, where a detailed itinerary and knowledge of ma-
laria epidemiology are needed. Up-to-date information on the
correct use, limitations, and drug interactions of current prior-
ity chemoprophylaxis agents (atovaquone/proguanil, meflo-
quine, doxycycline) is key. Another challenge is to identify
and reach travelers who are most at risk of malaria, such as the
traveler visiting friends and relatives. Posttravel, delays in
presentation, diagnosis, and inappropriate treatment of malaria
are key risk factors leading to death. Treatment of malaria is an
emergency requiring expert in-patient management and refer-
ral to a center with adequate expertise. Artemisinin combina-
tion therapies are the drugs of choice for uncomplicated ma-
laria. Complicated malaria is treated preferably with intrave-
nous artesunate, and the supply and quality of this life-saving
antimalarial in some settings can pose one of the most urgent
challenges in travelers’ malaria.
Keywords Malaria . Traveler . Chemoprophylaxis .
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Introduction
The prevention and treatment of malaria in travelers pose
important challenges in travel medicine. World Tourism
Organisation data suggest that there are approximately 180
million arrivals in malaria-endemic areas each year and that
the numbers are increasing with particular growth (+7 %) in
travel to sub-Saharan Africa, an area highly endemic for
malaria [41].
Malaria remains the most important, acute, and potentially
life-threatening tropical disease encountered by Western trav-
elers, as shown in a recent GeoSentinel multicenter study
where 76.9 % of returning travelers who presented with a
potentially fatal, travel-acquired illness were diagnosed with
Plasmodium falciparum malaria [1]. Travel health providers
are often confronted with complex scenarios when advising
travelers on malaria prevention. This article highlights the
most important current challenges.
Risk Rating
A major issue for travel health practitioners is malaria risk
assessment. Even the global risk of malaria in endemic areas is
hard to quantify, but recent data suggest that there are 250
million clinical cases per year, with about 800,000 deaths [42].
Areas at highest risk are in Africa and Southeast Asia, but
even within high-risk countries, many typical tourist destina-
tions are malaria free (Fig. 1,MalariaMap), so simply labeling
a country as “malaria endemic”will not provide enough detail
for risk assessment. For example, a traveler to Thailand,
officially a malaria-endemic country with some high-risk
areas, may visit only malaria-free areas such as Bangkok,
Phuket, or Ko Samui, and this individual will not need malaria
preventionmeasures. Several facets need to be included in this
risk analysis. The key question is, where is your traveler
going? A detailed itinerary and knowledge of malaria epide-
miology are needed. The intensity of malaria transmission at
the destination is probably the most important variable in the
risk analysis. Sub-Saharan Africa is considered a high-risk
region, whereas Southeast Asia and Central America have less
transmission (with some exceptions). To put this is in a nu-
merical context based on imported malaria cases per 100,000
travelers, malaria risk will vary from very high risk in Central
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Africa (estimated 357 cases per 100,000 travelers) to signifi-
cantly lower risk in Central America (estimated 1.3 cases per
100,000 travelers) [2, 3].
The species of malaria at the destination is also important,
and there is flux in malaria epidemiology. Most infections
imported to Europe and North America are Plasmodium
falciparum infections, and this species remains the biggest
threat (in terms of mortality) [4], but it is increasingly recog-
nized that the more widely distributed Plasmodium vivax is
not benign and also causes significant morbidity and, some-
times, fatal disease in travelers [4, 5•, 6]. A recent paper
examined the current failure of conventional malaria chemo-
suppression in preventing P. vivax malaria and called for a
new look at primaquine causal prophylaxis to prevent both
falciparum and vivaxmalaria [5•]. This is based on the knowl-
edge that primaquine taken daily during exposure to malaria
infection eliminates early developmental stages of the parasite
in the liver cycle (Fig. 2). Primaquine should be prescribed
only for G6PD-normal persons.
The “one health” concept is also important in travelers’
malaria. The entry of a new malaria species, Plasmodium
knowlesi, into the human population demonstrates a parasite
crossing to man from nonhuman hosts, monkeys [6]. Globally
speaking, the number of human infections with knowlesi is
small, but certain foci are important sources of this malaria,
and it is emerging as a risk for travelers to forested areas of
Southeast Asia and should be taken into account in the risk
assessment.
Traveler characteristics are also of vital importance in the
risk assessment. Travelers’ malaria has many faces and mul-
tiple facets, but those at highest risk of acquiring malaria are
travelers of African heritage who visit friends and relatives
(VFR) [3]. This poses a major challenge for travel health
providers, since VFR travelers are less likely to seek advice
prior to travel and may not be in a position to afford expensive
antimalarials. New approaches, perhaps with an emphasis on
primary health-care providers giving travel health advice, are
urgently needed to target the VFR traveler.
In contrast to the high risk of acquiring malaria in the
VFR group, the risk of dying from travelers’ malaria is
highest in business travelers and tourists, particularly the
elderly, and in returned travelers who present to clinics or
practitioners who have little or no experience in dealing with
malaria [1, 3]. Men are more likely to acquire malaria and
have more serious disease than women [7•]. Travelers to
high-risk areas really need to be convinced of the need for
effective malaria chemoprophylaxis medication and mos-
quito bite prevention.
Malaria map for travellers (adapted from WHO)
Cities / areas without malaria risk
Areas with very limited risk
Areas where malaria transmission occurs
Recife
Brasilia
Rio de Janeiro
São Paulo
Bogota
Quito
Lima
La Paz
Iguassu
Mexico City
Caracas
Harare
Nairobi(center)
Addis 
Ababa
Aden
Colombo
Jakarta
Kuala Lumpur
Penang
Singapore
Chiangmai
Bangkok
Pattaya
Phuket
Hong Kong
Macao
Shanghai
Manila
Belem
Khao Sok NP
Bali (resorts)
Beijing
Dubai
Fig. 1 Malaria map for travelers. (Adapted from WHO). Red shaded area indicates high risk African areas
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Chemoprophylaxis Conundrums
The next challenge is to prescribe an appropriate chemopro-
phylaxis. Factors such as drug efficacy, tolerability [7•],
price, and traveler characteristics will impact the choice. The
current priority antimalaria chemoprophylctic regimens are
atovaquone/proguanil, mefloquine, and doxycycline (Fig. 3).
Current guidelines, such as the CDCmalaria recommendations,
should be consulted for correct use and dosages of antimalarial
medication [43]. All the priority medication options are very
effective against malaria, except in some foci of multidrug-
resistant malaria in Thai border areas. Antimalarials are, how-
ever, associated with a high incidence of adverse events [7•, 8]
and it is worthwhile to discuss fears, myths, and facts regarding
these adverse events, since perception will impact traveler
behavior and adherence to the chemoprophylaxis. Matching
the traveler to the appropriate chemoprophylaxis can be
complex, especially for small children [8], travelers with
comorbidities, and the pregnant traveler. Atovaquone/
proguanil paediatric tablets are a good choice for children
(>11 kg in Europe, >5 kg in the U.S.) on short trips, or longer
term if the budget allows. Mefloquine is a practical, cost-
effective option for children (>5 kg) [8, 9•] who stay for longer
periods in malaria-endemic areas, but parents need to disguise
the bitter taste with chocolate or yoghurt. Doxycycline is less
frequently used for children (>12 years) (Table 1).
Older travelers are widening their travel expectations, often
despite comorbidities, and many questions arise when
recommending chemoprophylaxis where the traveler is already
taking several medications for routine conditions. A recent
U.S. study of adults 57–85 years of age showed that 81 %
are taking at least one prescription drug, 42 % are taking at
least one OTC drug, and 49 % are using dietary supplements.
The results of this study would suggest that 1 in 25 individuals
are at risk for a major drug–drug interaction. A thorough check
of traveler comorbidities and comedication is key. Some ex-
amples of important drug interactions are the following:
Travelers on warfarin may need INR checks or a change of
prophylaxis if using doxycycline or atovaquone/proguanil;
mefloquine should not be started until after the traveler has
completed taking his live oral typhoid fever vaccine. Tables 2,
3, and 4 show possible interactions that may occurwithmalaria
chemoprophylaxis.
The pregnant traveler poses a special challenge in malaria
chemoprophylaxis. Malaria during pregnancy poses a signif-
icant risk to the mother and foetus. Atovaquone/proguanil and
doxycycline are currently not recommended in pregnancy, but
mefloquine is an option, and a recent analysis has shown that
Fig. 2 Efficacy of anti-malarial drugs at various sites in the life cycle. (With permission from Schlagenhauf P, Funk M, PDQ Travelers' Malaria,
BC Decker 2005)
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the birth prevalence of malformations (4.4 %) in mefloquine-
exposed mothers is comparable to background levels [10••].
Personal Protection Problems
Travelers need concise information on antimosquito mea-
sures, and this preventive area is a real challenge. Surveys
have shown that adherence to personal protection measures
can be dismal. Remind the traveler of the simple fact: no
bite, no malaria. The female malaria mosquito, Anopheles,
bites at night. A combination of insect skin repellents (such
as DEET, IR3535, Icaridin) (Table 5), (pyrethroid)
insecticide-impregnated clothing, and bed nets/air condi-
tioning is effective in malaria prevention, but adherence to
these measures is poor, and time spent convincing the trav-
eler is well invested. It is also worthwhile to explode the
myths about measures that are ineffective, such as the use of
garlic, perfume, vitamin B complex, and ultrasound devices.
Diagnostic Dilemmas
Diagnostic tests for malaria should be performed in any ill
patient who has a history of exposure—that is, patients with a
history of travel to malaria-endemic areas, whether or not they
are febrile at presentation [12]. Health care facilities may not
have the expertise to do amicroscopic examination of thick and
thin Giemsa stained blood films. If patients with a history of
travel to malaria endemic areas and with fever can not have a
reliable microscopy or RDT for malaria, they should be re-
ferred to the nearest center, where these facilities and skills are
available. Microscopic examination of Giemsa-stained thin and
thick blood films remains the gold standard because it is rapid,
Chemoprophylaxis Choices 2013 
NON OPTION – Homeopathy
*The combination of chloroquine with proguanil is not available in N. America and is rarely used in Europe,
but is still used in the UK. 
Chloroquine 300mg base weekly
+proguanil 200mg daily* Primaquine (30mg base) daily
Priority Antimalarial
for chloroquine resistant Pf (CRPF)
Mefloquine
250mg WEEKLY
Atovaquone/proguanil
250mg/100mg daily
Doxycycline
100mg daily
Fig. 3 Chemoprophylaxis choices (2013)
Table 1 Antimalarial chemoprophylaxis for infants and small children
Anti-malarial Chemoprophylaxis Dosing Comments
Atovaquone/proguanil *>5 kg CDC >11 kg Europe, manufacturer -Daily -Palatable
-Pediatric tablets -Expensive
Chloroquine All ages and weights 5 mg base/kg Weekly -Limited use due to resistance
Doxycycline Children >12 years in Europe, > 8 years in U.S. 1.5 mg salt/kg Daily Contraindicated for small children
Mefloquine >5 kg 5 mg/kg Weekly - Bitter taste
- Weekly
Primaquine Children >4 years WHO CDC specifies
no lower age limit
0.5 mg/kg base Daily -G6PD testing essential
-Last choice
*new
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easy to perform, and sensitive [13], with a sensitivity down to
five parasites per microliter in expert hands. Thick blood films
have higher sensitivity compared to thin blood films because a
higher volume of blood is examined because the red blood cells
are lysed. The thin blood film are used to assist species diag-
nosis. It is important to diagnose malaria early, when it is
uncomplicated and only centers able to perform microscopy
should manage patients with malaria. After treatment has been
initiated a reduction in parasitemia may not be seen for another
24 hours. Rapid diagnostic tests including a pan-plasmodia
antigen can detect parasitmia as low as 200 parasites per
microliter [11]. PCR is not used in routine diagnosis as it is
not always available. However PCR is useful for confirmation
of the species diagnosis and for cases with low parasitemia
where microscopy may be doubtful and the rapid diagnostic
tests negative.
RDTs are increasingly used in medical centers with lim-
ited access to experienced microscopists; but, a rapid test
cannot determine the parasite density. False negative RDTs
in patients with very high parasite densities have been
described, probably due to the so-called “pro-zone” phe-
nomenon [12, 13]. This problem seems to be limited to tests
based on detection of circulating histidine-rich protein 2
(HRP2) [11]. Mutations in the HRP2 gene may result in
false negative tests [14, 15]. Assays are available that detect
all species—that is, P. falciparum, P. vivax, P. ovale, P.
malariae, and P. knowlesi—on the basis of the detection of
the panmalarial antigens aldolase and LDH [16].
Plasmodium knowlesi infections will be detected by rapid
tests, which include the pan-plasmodial aldolase or LDH
antigens [9•, 17].
The latest results of the World Health Organization
(WHO) multicenter evaluation of different rapid diagnostic
tests show that the best performance was found with tests
based on a combination of the HRP2 and pan-plasmodial
proteins [9•].
Clinicians using rapid tests need to be aware that no RDT
test so far is 100 % reliable and that blood film examinations
should be done in parallel. Because microscopy may be
negative especially in non-immunes with a very low
parasitemia, it is recommended that three blood films are
examined with approximately 24 hours interval to make
sure that patients presenting with low level parasitemia are
not missed. If the suspicion of malaria remains after three
negative samples, expert advice should be obtained from a
tropical or infectious disease specialist. After diagnosis,
daily blood films should be examined until they are negative
for asexual parasites (i.e., rings, trophozoites, schizonts).
Gametocytes do not multiply or cause clinical illness and
may remain after clearance of the asexual parasitaemia.
Tricky Treatments
In the U.K., between 1987 and 2006, 25,054 patients noti-
fied with Plasmodium falciparum, of whom 184 died [2].
Table 2 Possible interactions with mefloquine prophylaxis
Possible interaction with: Risks Consequence/Recomendation
Chloroquine ECG alterations. Convulsions Don‘t combine. Change to Doxy or At/P
Anticonvulsive drugs
(e.g., carbamazepine, phenytoin etc.)
Reduced plasma concentration of anti-convulsant Change prophylaxis to Doxy or At/P
Oral typhoid fever vaccine (Vivotif®) Inactivation of vaccine due to mefloquine Cannot be used concomitantly
Antihyperglycemics Blood sugar levels may be affected Control blood sugar levels
Cimetidine May increase MQ plasma levels Caution regarding increased risk of adverse events
Table 3 Possible interactions with atovaquone/proguanil prophylaxis
Possible interactions with: Risks Consequences/Recommendation
Metoclopramide, rifampicin, rifabutin Decrease serum concentration of
atovaquone/proguanil
Change to mefloquine or doxycycline
prophylaxis
Indinavir (HIV therapy) Atovaquone decreases plasma level
of indinavir by 23 %
Change to mefloquine or doxycycline
prophylaxis
Warfarin* Atovaquone may displace warfarin,
leading to increased serum warfarin
Single report* – monitor INR
Paracetamol, benzodiazepines, aciclovir, opiates,
cephalosporins, antidiarrheals, laxatives
Decrease the plasma concentration
of atovaquone
Importance unclear – probably not
crucial to change antimalarial
Oral typhoid fever vaccine (Vivotif®) NO interaction Can be used concomitantly
*Hidalgo et al. Ann Paharmacother 2011;45:e3 ** Faucher JF CID 200
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Delays in presentation, diagnosis, and appropriate treatment
of malaria were key risk factors, leading to death. Treatment
of malaria is an emergency and requires expert in-patient
management and treatment with fast acting antimalarials. A
recent position paper on the management of imported ma-
laria in Europe discussed malaria diagnostics and treatment
options and dilemmas [12, 31••].
Treatment should provide a rapid clinical and parasitologi-
cal cure within 3 days. Oral artemisinin combination treatment
(ACT) is the medication of choice for uncomplicated malaria,
as recommended by the WHO (Table 6) [18, 19]. Artemether/
lumefantrine (Riamet) and dihydroartemisinin/piperaquine
(Euartesim) are the two ACT formulations licensed for use in
Europe. Dihydroartemisinin/piperaquine is the first antimalar-
ial drug to be registered by the European Medicines Agency.
Artemether/lumefantrine is registered in the U.S. and is the
most widely used ACT globally. This combination is well
tolerated and highly efficacious in all endemic regions, except
for P. falciparum infections acquired in Cambodia and the
border regions of Thailand with Myanmar, where multidrug-
resistant P. falciparum strains are highly prevalent.
Artemether/lumefantrine should be administered with fatty
food to obtain optimal plasma drug concentrations [20].
Dihydroartemisinin/piperaquine, in contrast, should be taken
fasting.
Atovaquone/proguanil (Malarone) can be used as a first-
line treatment for uncomplicated malaria and needs to be
administered with fatty food to increase bioavailability.
Atovaquone/proguanil is relatively slow acting, with consid-
erably longer parasite clearance times, as compared with ACT.
Atovaquone/proguanil is the preferred treatment option for
uncomplicated falciparum malaria from regions with
artemisinin resistance (Cambodia, Thailand border regions).
Treatment of severe, complicated falciparum malaria: A
parasite density of 2 % or more in nonimmune and 5 % or
more in malaria-immune subjects is defined as severe. Severe
malaria may also be caused by species other than P.
falciparum, especiallyP. knowlesi. Plasmodium vivax can also
be severe in nonimmunes [21]. Severe imported P. falciparum
malaria is an emergency that may rapidly become fatal
[22].Intravenous artesunate (IVA) has been shown to be supe-
rior to intravenous quinine (IVQ) in overall survival and is
safer and simpler to administer [18, 23, 24]. A recent
Cochrane review concluded that treatment with artesunate
significantly reduced the risk of death in both adults (RR
0.61, 95 % confidence interval [CI] 0.50–0.75; 1,664 partic-
ipants, five trials) and children (RR 0.76, 95 % CI 0.65–0.90;
5,765 participants, four trials) [25]. Intravenous artesunate
must be started immediately after the confirmation of the
diagnosis, and the patients should be transferred to the ICU
for management.
A recent study reported haemolytic anaemia in 6 out of 25
patients treated with IVA for severe imported malaria diag-
nosed 14–31 days after the first dose of IVA [26]. A larger
Table 5 Repellents: Pros and cons
Repellent Advantages Disadvantages
DEET Widely used and tested, effective 20 % DEET protects for >5 h* May damage fabrics and plastics
Bayrepel® Picaridin KBR 3023 19.2 % preparation similar protection to DEET best against
An gambiae** Less irritating than DEET
Interindividual variation
EBAAP IR3535 Mean protection 23 min* Good cosmetic properties Variation in efficacy
PMD Eucalyptus citriodora 96%protection for up to 4 h Plant-based repellent Well tolerated Interindividual variation with
lemon eucalyptus
Natural Oils “Bio” – high acceptance (Very) short protection duration
Table 4 Possible interactions with doxycycline
Possible interaction with: Risks Consequences/Recommendations
Warfarin anticoagulants Anticoagulant effect of warfarin is enhanced Control prothrombin time (INR) or change
prophylaxis
Antacids (with Mg, Ca, Al), laxatives,
oral iron, antidiarrheals
Agents bind with doxcycline Take 3 h after doxy
Carbamazepine. Barbiturates, phenytoin
Glucose urinary tests
Decrease half-life of doxycycline Change prophylaxis or dosage adjustment
of doxy (2×)
Glucose urinary tests May be false negative or positive Control blood sugar
Oral typhoid fever vaccine Vaccine effectiveness may be reduced Complete prior to Doxy prophylaxis
Digoxin Serum digoxin may be increased Limited data – no reports of toxicity
Oral contraceptives Decrease in contraceptive effect? No solid evidence
*CYP3A4 inhibitor (moderate)
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study including 55 patients with severe malaria reported late
onset haemolytic anaemia in 6 patients (9 %) between 7 and
31 days after start of IVA [27], and three more cases have been
reported [28]. In a large French study of about 400 severe
malaria patients treated with IVQ in the ICU, 28.5 % of them
required red blood cell transfusion for marked anaemia [29].
Patients should be monitored for 4 weeks following IVA for
haemolysis and leukopenia. It is unclear whether this condition
can occur after treatment with artemether/lumefantrine, but a
single case has been reported in the literature [30]. IVA should
be completedwith a full course of ACT, atovaquone/proguanil,
or mefloquine.
The management and treatment of complicated malaria
should be centralized, and the patient should be transferred
to a center where intravenous artesunate, skills in microscopy.
Detailed recommendations can be found in a recent position
paper on management of imported malaria in Europe [31••].
Tricky Treatment of P. vivax, P. ovale, P. malariae,
and P. knowlesi
Plasmodium ovale and P. malariae generally remain sensitive
to chloroquine in all endemic areas, despite reports of delayed
parasite clearance time [32]. Plasmodium vivax sensitivity to
chloroquine has declined steadily in Indonesia, Peru, and
Oceania [19], and a paradigm shift is imminent, with opinion
leaders beginning to call for a switch to ACT as the drug of
choice in Indonesia, Peru, and Oceania. The use of
artemether/lumefantrine has been suggested as a pragmatic
choice in areas with chloroquine-resistant P. vivax [33].
Mefloquine (15 mg/kg body weight as a single dose) has
been found to be highly effective against P. vivax, with a
treatment success of 100 % [34]. Monotherapy with doxy-
cycline (100 mg twice a day for 7 days) results in poor cure
rates against P. vivax [35], but quinine is also effective
against chloroquine-resistant P. vivax, but it is not an ideal
treatment because of low tolerability and the possibility of
early relapses [34]. The first-line treatment for P. vivax is
chloroquine, with ACT as second line if the response to
chloroquine is poor.
Plasmodium vivax and P. ovale infections, but not P.
malariae, require treatment with primaquine for 14 days to
eradicate liver hypnozoites (Fig. 2). Primaquine is contrain-
dicated in patients with deficiency of the enzyme glucose-6-
phosphate dehydrogenase (G6PD) [36]. Plasmodium vivax
strains with reduced susceptibility to primaquine are found
in southern regions of Oceania and Southeast Asia and
require a higher dose of primaquine (up to 0.75 mg/kg/day,
max 30 mg per day) for 14 days to prevent relapses [37].
Primaquine 30 mg per day in adults tested negative for
G6PD deficiency should be standard treatment for adult
patients with P. vivax and P. ovale after G6PD testing [38].Ta
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Primaquine should be administered concomitantly with a
partner blood schizonticide.
Treatment of P. knowlesi is not standardized. A patient
suspected of P. knowlesi infection should be referred for
expert diagnosis and treatment. Uncomplicated P. knowlesi
cases can be treated with ACT, chloroquine, quinine, or
atovaquone/proguanil [39]. A recent study showed that ACT
cleared parasites faster than did comparator antimalarials. In
severe P. knowlesi cases, the use of IVAwas associated with a
lower case-fatality rate (17 % vs. 31 %) and lower median
parasite clearance time (2 days vs. 4 days) than was IVQ [40].
Thus, uncomplicated P. knowlesi should be treated with
chloroquine or an ACT drug, and complicated P. knowlesi
with IVA.
Conclusions
The prevention and treatment of travelers malaria is highly
challenging. The pretravel risk assessment is key to defining
the type and intensity of malaria transmission at the desti-
nation and to prescribing appropriate antimalarials that are
individually tailored. Special attention to individual charac-
teristics is essential. Risk groups, such as pregnant
women, expatriate travelers, small children, the elderly,
and those on polymedication, need special attention.
The most important challenge for travel health advisers
and, indeed, for returned travelers is simply to “think ma-
laria” when there is a suggestive travel history and to act
promptly in case of fever. Treatment of malaria is an emer-
gency and requires expert in-patient management and treat-
ment with fast-acting antimalarials. Delays in presentation
and diagnosis and inappropriate treatment of malaria are key
risk factors leading to death.
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